Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)

2) A method of treating non-insulin dependent diabetes mellitus in a patient comprising administering to the patient an antagonist of glucose-dependent insulinotropic polypeptide (GIP).

3) A method of improving glucose tolerance in a non-insulin dependent diabetes mellitus patent comprising administering to the patient an antagonist of glucose-dependent insulinotropic polypeptide (GIP).

4) A method of preventing, inhibiting or reducing obesity in an animal comprising administering to the animal an antagonist of glucose-dependent insulinotropic polypeptide (GIP) to inhibit, block or reduce glucose absorption from the intestine of the animal.

8) An antagonist of glucose-dependent insulinotropic polypeptide (GIP).

11) A pharmaceutical composition for preventing, inhibiting or reducing obesity in an animal comprising:

• an effective amount of an antagonist of glucose-dependent insulinotropic polypeptide (GIP) to inhibit, block or reduce glucose absorption from the intestine of the animal;
• and
• an acceptable pharmaceutical carrier.

17) A method of developing a nonpeptide GIP antagonist comprising:

• using a GIP antagonist to identify characteristics of the GIP antagonist or the antagonist properties of a GIP antagonist;
• and
• developing a nonpeptide GIP antagonist which has characteristics similar to the GIP antagonist or antagonist properties of the GIP antagonist.